secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001599298-26-000037
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Q1 net loss $189.4M, cash $598.7M; ivonescimab OS data at ASCO plenary
-----------------------------------------------------------------------------

- GAAP net loss $189.4M ($0.24/sh) vs $62.9M ($0.09/sh) YoY; non-GAAP net loss $116.6M ($0.15/sh).
- Cash and short-term investments $598.7M, down $114.7M from Dec 2025; cash burn funds ivonescimab trials.
- HARMONi-6 (squamous NSCLC in China) OS data to be presented at ASCO 2026 plenary as late-breaking abstract.
- HARMONi-3 squamous final PFS expected H2 2026; interim PFS cleared by iDMC, study continues blinded.
- BLA for ivonescimab in EGFR-mutated NSCLC accepted; PDUFA date Nov 14, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000037/0001599298-26-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000037/smmt-20260430.htm
  HTML page:      https://secwatch.observer/filing/0001599298-26-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer